NEW YORK (GenomeWeb News) — Dutch company Genmab has extended its agreement to use ID Business Solutions’ ActivityBase Xtended Edition screening software, Guildford, UK-based IDBS said today.
Under the agreement, Genmab’s Hybridoma Discovery department will use the software to mange the design, capture, storage, and retrieval of plate-based screening data, IDBS said.
IDBS said Genmab initially licensed the software in 2006 to manage data from functional screening of human monoclonal antibody therapies, and now has “more than doubled” that number of ActivityBase XE licenses.
IDBS’ founder and CEO Neil Kipling said the software supports high-throughput and high-content screening and “new screening methodologies.”
Financial terms of the agreement were not released.